All Themes

CMS is shifting VBC momentum back toward federal mandatory models, with the Trump administration proposing CJR-X as a nationwide mandatory joint-replacement bundle beginning in 2028—giving hospitals, specialists, SNFs, and home health providers time to redesign episode economics, referral networks, and post-acute performance management around downside-risk bundles ([HFMA](https://www.hfma.org/payment-reimbursement-and-managed-care/cjr-x-mandatory-bundled-payment-model/)). At the same time, DOJ enforcement against Medicare Advantage risk-adjustment abuse—including large settlements involving Complete Health and The Villages Health—signals that coding-driven VBC economics are facing sharper scrutiny, raising the strategic premium on defensible documentation, clinical validation, and population-health infrastructure over pure RAF optimization ([Healthcare Dive](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/)). For ACOs, payers, and provider platforms, the throughline is a pivot from MA-led growth toward CMS-directed accountability models, with opportunity for organizations that can manage episodes and total cost of care—but rising compliance and operational risk for those whose VBC playbooks depend heavily on diagnosis capture.

CMS is pushing affordability through more prescriptive payment and utilization-management levers: the Trump administration finalized a 2.3% Medicare inpatient payment update for 2027 while also moving toward a nationwide mandatory joint-replacement bundled payment model beginning in 2028, signaling renewed pressure on hospitals to manage episode cost, post-acute utilization, and implant variation under downside risk ([Healthcare Dive](https://www.healthcaredive.com/news/medicare-finalizes-hospital-inpatient-pay-raise-2027/826794/)). At the same time, CMS is tightening prior authorization transparency requirements across Medicare Advantage, Medicaid managed care, and ACA marketplace plans, which could reduce administrative friction but also expose plan-provider tensions around denial patterns, turnaround times, and digital prior authorization performance ([HFMA](https://www.hfma.org/revenue-cycle/cms-prior-authorization-transparency-requirements/)). For VBC stakeholders, the strategic throughline is clear: affordability policy is shifting from voluntary transformation rhetoric toward mandatory bundles, plan accountability, rural-capacity investment, and Medicaid demonstrations such as BALANCE for GLP-1 coverage—raising the premium on data integration, specialty cost management, and payer-provider contracting discipline.

CMS is moving decisively toward mandatory downside-risk models under the Trump administration, with the FY27 IPPS/LTCH proposed rule establishing CJR-X as a nationwide mandatory joint replacement bundle beginning in 2028—forcing hospitals, post-acute providers, and home health partners to prepare for episode-cost accountability, discharge optimization, and preferred-network management well before the start date ([HFMA](https://www.hfma.org/payment-reimbursement-and-managed-care/cjr-x-mandatory-bundled-payment-model/)). At the same time, CMS’s CY 2027 Physician Fee Schedule proposals would continue refining MSSP requirements, while the LEAD Model is drawing attention from in-home primary care operators, signaling a broader policy push to align primary care, specialty episodes, and longitudinal population health infrastructure. The strategic tension for VBC organizations is intensifying: CMS is expanding mandatory participation and model complexity while DOJ enforcement against Medicare Advantage risk adjustment and upcoding—seen in major settlements involving Complete Health and Humana-owned The Villages Health—raises the compliance bar for coding-driven revenue strategies.

CMS is pushing care coordination from a “nice-to-have” capability into a payment-model requirement, with mandatory joint-replacement expansion through TEAM creating stronger incentives for hospitals to manage referrals, discharge planning, home health relationships, and post-acute spend across episodes of care. At the same time, NCQA’s move toward person-centered outcome measures for SNPs and ECDS-based Transitions of Care reporting signals that referral management and care-plan execution will increasingly be judged through digital, patient-centered quality infrastructure—not just claims lag or process documentation. For ACOs, hospitals, home health agencies, and payers, the strategic pressure is converging around building preferred post-acute networks, specialist alignment, and interoperable care-transition workflows before expanded accountability models such as [TEAM](https://www.cms.gov/priorities/innovation/innovation-models/team-model) and digital quality requirements like [HEDIS ECDS Transitions of Care](https://www.ncqa.org/blog/the-hedis-transitions-of-care-measure-is-moving-to-ecds-reporting-how-you-can-start-preparing-now/) become operational constraints.

CMS is increasingly becoming the primary engine for value-based care expansion as Medicare Advantage plans pull back on risk appetite and tighten utilization management, including elevated prior authorization denials; this shifts strategic focus for primary care, home-based care, and post-acute providers toward CMS/CMMI models rather than MA-only growth strategies. Primary care and in-home care organizations are positioning around models such as LEAD and TEAM to prove longitudinal, post-acute, and home-based care value, while NCQA’s HEDIS MY 2027 person-centered outcome measures and ECDS transition-of-care reporting signal that future VBC performance will depend more heavily on digital quality infrastructure and patient-defined goals. For ACOs, payers, and health systems, the near-term tension is whether CMS-led payment models can create enough predictable upside to offset MA retrenchment and administrative friction while accelerating care delivery transformation in primary care and the home ([CMS as VBC engine](https://homehealthcarenews.com/2026/08/cms-emerges-as-value-based-cares-new-engine-as-medicare-advantage-plans-pull-back/); [LEAD and in-home primary care](https://homehealthcarenews.com/2026/08/bloom-healthcare-looks-to-lead-model-technology-to-support-in-home-primary-care/)).

CMS’s CY 2027 Physician Fee Schedule proposals are pushing quality measurement further into the core economics of VBC, with MSSP and Quality Payment Program changes signaling tighter alignment between ACO performance, MIPS pathways, and Medicare payment updates under the Trump administration’s CMS leadership. At the same time, NCQA’s approval of person-centered outcome measures for HEDIS MY 2027 and the shift of Transitions of Care to ECDS reporting accelerate the move from claims/manual abstraction toward digital, patient-reported, and interoperable quality infrastructure—raising execution pressure on ACOs, MA plans, D-SNPs, C-SNPs, and provider groups. For VBC stakeholders, the strategic tension is clear: quality programs are becoming more clinically meaningful and data-rich, but also more operationally demanding, requiring investment in EHR integration, patient engagement workflows, and measure governance ahead of 2027 implementation timelines ([HFMA on CY 2027 QPP](https://www.hfma.org/payment-reimbursement-and-managed-care/cy-2027-physician-fee-schedule-proposed-rule-summary-part-iii-quality-payment-program/); [NCQA on HEDIS MY 2027 person-centered outcomes](https://www.ncqa.org/blog/person-centered-outcome-measures-are-approved-for-hedis-my-2027/)).

Provider and payer strategies are converging around population health infrastructure: Franciscan Alliance’s partnership with Elevance-backed Millennium Physician Group signals continued consolidation of value-based enablement capabilities—risk contracting, care management, analytics, and physician alignment—into regional delivery networks aiming to scale performance across Indiana. At the same time, condition-specific networks are tightening around measurable outcomes, with kidney-care stakeholders emphasizing “high-value” network design as payers narrow participation based on cost, quality, and longitudinal management performance ([Franciscan–Millennium partnership](https://news.google.com/rss/articles/CBMiuwFBVV95cUxNb3p2Q2l6V1lnX1dUXzZJa3FfWHEtbmYxQl9KRnA2Y3JlT3BVd08xWU1sWUJIRWh0SFZuYi1KWlBOTmRBMHJuN2h3NGdwY09QM2IzM1VOWi1pNDJDb1JWVU9pRm9sMjQ4aHo2d2laY2hIN25TZXhvaVEwTEhHcnFFWG8xdXhOVWNZTDN3TjBVR2NreU9kZm1IVXJhNkp0QlB0cHJpQWg5a3hma0NHdjB4M2Q0XzRmZEV5Y3A

CMS is tightening the operational infrastructure for value-based care by pushing payers toward more transparent, FHIR-enabled prior authorization processes across Medicare Advantage, Medicaid managed care, ACA marketplace plans, and state Medicaid/CHIP programs—raising the bar for plans and risk-bearing providers that depend on timely utilization management data and reduced administrative friction ([HFMA](https://www.hfma.org/revenue-cycle/cms-prior-authorization-transparency-requirements/)). At the same time, NCQA is accelerating the move from claims/hybrid quality reporting to digital, person-centered measurement, with HEDIS MY 2027 adding person-centered outcome measures for D-SNPs and C-SNPs and moving Transitions of Care toward ECDS reporting—signaling that VBC performance will increasingly hinge on interoperable clinical data, care-plan documentation, and patient-reported goals rather than retrospective claims alone ([NCQA](https://www.ncqa.org/blog/person-centered-outcome-measures-are-approved-for-hedis-my-2027/)). Together, these shifts create a strategic tension for ACOs, MA plans, and Medicaid managed care organizations: interoperability investments are becoming table stakes for both payment-model execution and quality performance, but implementation burden will fall unevenly across provider networks with variable EHR, FHIR, and analytics maturity.

CMS and state Medicaid policy are moving health equity/SDoH from reporting rhetoric into financing mechanics: Section 1115 budget-neutrality guidance is shaping how states fund HRSN, coverage expansions, and delivery reforms, while Indiana’s use of the federal BALANCE Model to cover GLP-1 obesity drugs signals a growing willingness to test high-cost interventions through population-health and Medicaid VBC frameworks. In Medicare Advantage, the equity debate is sharpening around whether Star Ratings and utilization management should adjust for social risk, as recent analyses argue for [social risk–weighted MA scoring](https://www.ajmc.com/view/social-risk-weighted-scoring-to-improve-medicare-advantage-star-ratings) and find prior authorization burdens vary with county social vulnerability—raising strategic stakes for plans, ACO partners, and providers serving disadvantaged populations. For VBC stakeholders, the near-term tension is whether CMS and states can align risk adjustment, quality measurement, prior authorization transparency, and Medicaid eligibility/work-requirement policy without penalizing organizations that take accountability for higher-need populations.

Payment integrity pressure on Medicare Advantage risk adjustment is intensifying, with DOJ settlements against value-based and MA-affiliated providers—including Complete Health’s $14M upcoding settlement and The Villages Health’s reported $542M settlement—signaling that coding-driven VBC economics face rising False Claims Act exposure when diagnosis capture is not tightly supported by clinical documentation and compliance controls. For ACOs, MA groups, and payer-owned delivery assets, the strategic risk is shifting from retrospective RADV-style audit exposure to broader enforcement against population-health documentation workflows, provider incentives, and risk-score operating models, while CMS’s prior authorization transparency requirements add another layer of plan accountability around utilization management and administrative data flows. See: [Complete Health settlement](https://www.healthcaredive.com/news/complete-health-doj-settlement-medicare-false-claims-upcoding/826983/) and [The Villages Health settlement](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/).

Recent Medicare Advantage developments point to a sharper enforcement and compliance environment around risk adjustment, with DOJ settlements against value-based and MA-aligned providers—including [Complete Health’s $14M settlement](https://www.healthcaredive.com/news/complete-health-doj-settlement-medicare-false-claims-upcoding/826983/) and [The Villages Health’s $542M settlement](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/)—underscoring that diagnosis capture, coding governance, and provider-delegated risk arrangements are now core enterprise risk issues for VBC organizations. At the same time, quality measurement is moving toward more person-centered accountability, with NCQA preparing person-centered outcome measures for HEDIS MY 2027 in D-SNPs and C-SNPs, increasing the strategic importance of care planning, member engagement, and defensible documentation as MA Stars economics remain pressured and plans reassess participation, benefits, and provider partnerships.

CMS is moving prior authorization from a payer-by-payer operational nuisance toward a regulated transparency and interoperability regime: updated requirements for MA, Medicaid managed care, and ACA Marketplace plans build on electronic prior authorization rules, while new public metrics show standard PA denial rates of at least 1 in 8 across major markets and wide insurer variation, creating new benchmarking pressure for plans and contracting leverage for providers and ACOs ([KFF analysis](https://www.kff.org/patient-consumer-protections/prior-authorization-metrics-provide-new-insights-into-insurer-practices-but-gaps-remain/); [HFMA summary](https://www.hfma.org/revenue-cycle/cms-prior-authorization-transparency-requirements/)). For VBC stakeholders, the strategic issue is shifting from “reduce administrative burden” to “govern utilization management as a measurable component of network performance, patient access, and total-cost accountability,” especially in Medicare Advantage where high denial variation can affect referral management, post-acute access, quality scores, and provider willingness to enter risk. Technology vendors and health systems are responding with FHIR-enabled and EHR-embedded prior authorization workflows—such as Epic’s instant PA checks—positioning automation as both a compliance tool and a care-continuity lever, but the unresolved tension is whether faster PA infrastructure will meaningfully curb inappropriate denials or simply make utilization controls more scalable.

Risk adjustment enforcement is moving from episodic compliance risk to a core strategic constraint for VBC organizations, as DOJ actions against MA-linked providers—including Complete Health’s $14M settlement for allegedly false diagnosis submissions and The Villages Health’s $541M+ settlement over alleged fabricated MA codes—signal heightened scrutiny of coding-driven revenue models in delegated-risk, primary care, and payer-owned assets. For ACOs, MA groups, and population health platforms, the near-term implication is a shift from growth-through-capture to defensible documentation, clinical validation, and audit-ready governance—especially as CMS under the Trump administration continues to pressure payment integrity while expanding mandatory model activity such as the forthcoming nationwide joint replacement model. See coverage of [Complete Health’s settlement](https://www.healthcaredive.com/news/complete-health-doj-settlement-medicare-false-claims-upcoding/826983/) and [The Villages Health settlement](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/).

CMS is moving bundled payments back toward mandatory, hospital-led accountability: the FY27 IPPS/LTCH final rule finalized CJR-X, a nationwide mandatory joint replacement bundle beginning January 1, 2028, giving hospitals roughly 17 months to prepare for episode-cost, quality, post-acute network, and data-operating requirements under the Trump administration’s CMS leadership ([HFMA](https://www.hfma.org/payment-reimbursement-and-managed-care/cjr-x-mandatory-bundled-payment-model/)). The strategic signal is broader than orthopedics: CJR-X, TEAM, and proposed updates to specialty models such as the Ambulatory Specialty Model indicate CMS is becoming the primary engine of VBC expansion as Medicare Advantage plans pull back, creating opportunity for home health and post-acute providers to prove episode-value—but also intensifying hospital concerns about administrative burden, with new research estimating existing mandatory VBP programs already add billions in annual hospital costs ([Home Health Care News](https://homehealthcarenews.com/2026/08/cms-emerges-as-value-based-cares-new-engine-as-medicare-advantage-plans-pull-back/)).

CMS’s CY 2027 Physician Fee Schedule proposal is keeping MSSP at the center of Medicare value-based care strategy, with stakeholders scrutinizing how benchmark, quality, and participation requirements will affect ACO economics and whether smaller/rural providers can realistically enter or remain in downside-risk arrangements. At the same time, the Trump CMS innovation agenda is pushing adjacent models—LEAD for in-home primary care, TEAM/CJR-X for episodes, and condition-based specialty models—toward tighter integration with ACO infrastructure, creating a strategic imperative for ACO REACH and MSSP participants to build post-acute, home-based, specialty, and technology-enabled care management capabilities rather than relying on primary care attribution alone. See HFMA’s breakdown of proposed [CY 2027 MSSP requirements](https://www.hfma.org/payment-reimbursement-and-managed-care/cy-2027-physician-fee-schedule-proposed-rule-summary-part-ii-mssp-requirements/) and NAACOS’s framing of care-transformation readiness for [CJR-X](https://news.google.com/rss/articles/CBMinAFBVV95cUxPdmhBdWtxa2xMMS1BY3BBX1VmbWpYVmJWeDQ5MTdNZzlta25iWHQzRnU1YmF4aElubnpXbnJpTUwxUjViVldTLURJenFIMklUcmlORm02d

CMS’s CY 2027 Medicare Physician Fee Schedule proposal is shaping up as a strategic payment signal from CMS toward primary care, care management, and MSSP infrastructure—potentially improving the economics of longitudinal, team-based care while adding new operational requirements for ACOs participating in the Medicare Shared Savings Program ([HFMA MSSP summary](https://www.hfma.org/payment-reimbursement-and-managed-care/cy-2027-physician-fee-schedule-proposed-rule-summary-part-ii-mssp-requirements/)). At the same time, proposed RPM/RTM and Medicare care management changes would tighten oversight and documentation expectations, creating tension between CMS’s push for scalable population health tools and provider/vendor concerns that compliance burdens could disrupt remote monitoring adoption ([CMS 2027 RPM/RTM changes](https://www.newswire.com/news/cms-2027-proposed-rule-key-changes-to-rpm-rtm-and-medicare-care-22848994)). For VBC leaders, the core takeaway is that CMS is continuing to rebalance fee-for-service toward primary care and accountable care capabilities, but organizations will need stronger coding, attribution, technology governance, and care-management audit readiness to capture the upside.

Specialty value-based care is moving from broad primary-care attribution toward condition-specific performance networks, with CMS under the Trump administration refining the Ambulatory Specialty Model for heart failure while cardiology groups prepare for new requirements around data, referral coordination, and accountability for total-cost outcomes ([ACC readiness guide](https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools-and-Practice-Support/Advocacy-at-the-ACC/E26030-ASM-Readiness-Guide.pdf)). In kidney care, payers are increasingly narrowing networks around measurable outcomes and partnering with specialty enablement firms, but persistent CKD diagnosis gaps and limited movement in hospital cost trends underscore a core VBC tension: investment is flowing into specialty risk models faster than upstream identification, attribution, and avoidable-utilization levers are maturing ([Strive Health](https://strivehealth.com/news/why-high-value-networks-matter-more-than-ever-in-kidney-care/)). For ACOs, MA plans, and health systems, the strategic implication is that specialty-care models are becoming a contracting and network-design battleground—success will depend less on participation alone and more on proving longitudinal co-management, timely diagnosis, and specialty-specific cost control.